GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bausch + Lomb BLCO · USD

Health Care · US listing · 🇺🇸 United States

Compare

20.96

+4.85%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$5.10bn

FY2018FY2025

Net income

−$360.0m

FY2018FY2025

Free cash flow

−$66.0m

FY2018FY2025

Shareholders' equity

$6.45bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$5.10bn$4.79bn$4.15bn$3.77bn$3.77bn$3.41bn$3.78bn$3.67bn
Gross profit$2.79bn$2.92bn$2.50bn$2.25bn$2.30bn$2.13bn$2.45bn$2.35bn
Research and development$371.0m$343.0m$324.0m$307.0m$271.0m$281.0m$258.0m$221.0m
Operating income$188.0m$162.0m$130.0m$213.0m$329.0m$260.0m$396.0m$416.0m
Net income−$360.0m−$317.0m−$260.0m$6.0m$182.0m−$18.0m$298.0m$710.0m
Diluted earnings per share-1.02-0.90-0.740.020.52-0.050.852.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$14.02bn$13.47bn$13.44bn$11.14bn$10.82bn$11.27bn$11.47bn—
Cash and short-term investments$383.0m$305.0m$334.0m$380.0m$174.0m$238.0m$192.0m—
Total liabilities$7.50bn$6.92bn$6.52bn$4.04bn$1.42bn$1.28bn$1.44bn—
Debt$5.08bn$4.78bn$4.56bn$2.44bn————
Shareholders' equity$6.45bn$6.47bn$6.85bn$7.03bn$9.33bn$9.92bn$9.96bn—
Shares outstanding354m352m351m350m350m351m350m350m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations$283.0m$232.0m−$17.0m$345.0m$873.0m$522.0m$799.0m$763.0m
Capital spending−$349.0m−$291.0m−$181.0m−$175.0m−$193.0m−$259.0m−$180.0m−$101.0m
Free cash flow−$66.0m−$59.0m−$198.0m$170.0m$680.0m$263.0m$619.0m$662.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.39bn$1.24bn$1.41bn$1.28bn$1.28bn$1.14bn$1.28bn$1.20bn
Gross profit$821.0m$704.0m$816.0m$703.0m$686.0m$588.0m$779.0m$732.0m
Operating income$83.0m$59.0m$158.0m$80.0m$11.0m−$61.0m$87.0m$43.0m
Net income−$14.0m−$71.0m−$58.0m−$28.0m−$62.0m−$212.0m−$3.0m$4.0m
Diluted earnings per share-0.04-0.20-0.16-0.08-0.17-0.60-0.010.01
Cash from operations$153.0m$32.0m$134.0m$139.0m$35.0m−$25.0m$22.0m$154.0m
Capital spending−$71.0m−$100.0m−$72.0m−$74.0m−$89.0m−$110.0m−$92.0m−$60.0m
Free cash flow$82.0m−$68.0m$62.0m$65.0m−$54.0m−$135.0m−$70.0m$94.0m
Total assets$13.86bn$13.78bn$14.02bn$13.83bn$13.83bn$13.43bn$13.47bn$13.52bn
Cash and short-term investments$367.0m$268.0m$383.0m$310.0m$272.0m$202.0m$305.0m$329.0m
Debt$5.12bn$5.07bn$5.12bn$4.95bn$4.96bn$4.83bn$4.82bn$4.63bn
Shareholders' equity$6.38bn$6.38bn$6.45bn$6.43bn$6.44bn$6.36bn$6.47bn$6.59bn

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin54.8%60.9%60.4%59.7%61.0%62.3%
Operating margin2.2%3.4%2.8%5.8%8.4%8.5%
Net margin-7.1%-6.6%-6.3%0.2%4.8%-0.5%
Return on equity-5.6%-4.9%-3.8%0.1%2.0%-0.2%
Return on assets-2.6%-2.4%-1.9%0.1%1.7%-0.2%
Free cash flow yield11.3%9.4%3.0%9.4%19.3%14.1%
Revenue growth6.5%15.6%10.0%0.1%10.3%-9.7%
Earnings growth13.6%21.9%-4433.3%-96.7%-1111.1%-106.0%
Current ratio1.55x1.60x1.74x1.65x1.49x1.82x
Debt to equity0.79x0.74x0.67x0.35x0.01x0.00x
Equity ratio46.0%48.1%51.0%63.1%86.2%88.0%
Interest coverage0.26x0.41x0.41x1.50x5.05x15.26x
R&D as a share of sales7.3%7.2%7.8%8.1%7.2%8.2%
Buybacks as a share of market value-0.7%-0.3%-0.2%0.0%0.4%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.9%6.5%—
Operating income-4.1%-6.3%—
Net income—82.1%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin57.7%58.8%59.6%—
Operating margin3.5%3.9%5.1%—
Net margin-6.8%-5.2%-3.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-16.8-20.0-23.0—
Price to sales1.31.41.61.5

Market value over time

31 May 2022 to 13 Oct 2026, in USD

$5.95bn$5.65bn

Share price return

Finished calendar years

2025202420232022
Return-7%18%5%-26%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.